SOR-C13 is the leading drug in a phase 1b trial in pancreatic cancer

SOR-C13 is the leading drug in a phase 1b trial in pancreatic cancer

Cancer-News

9 months
159 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Jack Stewart, CSO of Soricimed Biopharma explains SOR-C13 is the leading drug in a phase 1b clinical trial in late stage pancreatic cancer.
Up Next Autoplay